US equities |
SPCX $168.43 ▲+5.96% NVDA $237.29 ▲+1.43% MU $1,066.27 ▼-0.80% TSLA $378.69 ▲+2.19% MSFT $525.54 ▲+1.55% SNDK $1,714.50 ▼-0.32% INTC $117.23 ▼-1.76% META $743.30 ▲+2.09%
FinancialContent

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

1.020 -0.020 (-1.92%)
Delayed Quote Updated: 1:09 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Crude Oil Down 2%; US Durable Goods Orders Decline In July ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
News headline image
US Stocks Mixed; American Woodmark Posts Downbeat Sales ↗
 
Via Benzinga
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Today: S&P 500, Nasdaq Futures Decline— Palo Alto, XP, Allarity Earnings In Focus ↗
U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower. 
Via Benzinga
Topics Stocks
News headline image
Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Changes to Board of Directors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert ↗
U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s... 
Via Benzinga
Topics World Trade
News headline image
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week ↗
Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among... 
Via Stocktwits
News headline image
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >